Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
|
| In millions, except per share items | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Atherosclerosis | | | | | | | | 5,552.1 |
| Vaccines and Infectious Diseases | | | | 2,244.7 | 984.2 | 1,070.3 | 1,056.1 | 1,028.3 |
| Hypertension/heart failure | | | | | | | | 3,477.8 |
| Other | | | | 20,391.3 | 21,027.7 | 21,902.5 | -1,056.1 | 11,387.6 |
| Total revenues | 23,643.2 | 23,850.3 | 24,197.7 | 22,636.0 | 22,011.9 | 22,972.8 | 0.0 | 21,445.8 |
| Revenue growth [+] | -0.9% | -1.4% | 6.9% | 2.8% | -4.2% | | -100.0% | 1.2% |
| Vaccines and Infectious Diseases | | | | 128.1% | -8.0% | 1.3% | 2.7% | |
| Cost of goods sold | 5,590.8 | 5,582.5 | 6,140.7 | 6,001.1 | 5,149.6 | 4,965.7 | 4,436.9 | 4,004.9 |
| Gross profit | 18,052.4 | 18,267.8 | 18,057.0 | 16,634.9 | 16,862.3 | 18,007.1 | -4,436.9 | 17,440.9 |
| Gross margin | 76.4% | 76.6% | 74.6% | 73.5% | 76.6% | 78.4% | | 81.3% |
| Selling, general and administrative | 7,323.8 | 7,377.0 | 7,556.7 | 8,165.4 | 7,155.5 | 7,238.7 | 6,200.3 | 5,652.2 |
| Research and development | 5,139.2 | 4,805.3 | 4,882.8 | 4,782.9 | 3,848.0 | 4,010.2 | 3,279.9 | 2,677.2 |
| Equity in earnings | 2,503.0 | 2,560.6 | 2,976.5 | 2,294.4 | 1,717.1 | 1,008.2 | -474.2 | 644.7 |
| Other operating expenses | | | | -142.3 | -322.2 | -107.6 | -14,111.7 | |
| EBITDA [+] | 9,754.6 | 10,277.3 | 10,582.2 | 8,391.7 | 9,606.2 | 9,324.7 | 1,034.6 | 10,987.4 |
| EBITDA growth | -5.1% | -2.9% | 26.1% | -12.6% | 3.0% | 801.3% | -90.6% | -2.2% |
| EBITDA margin | 41.3% | 43.1% | 43.7% | 37.1% | 43.6% | 40.6% | | 51.2% |
| Depreciation and amortization | 1,662.2 | 1,631.2 | 1,988.2 | 2,268.4 | 1,708.1 | 1,450.7 | 1,314.2 | 1,231.2 |
| EBIT [+] | 8,092.4 | 8,646.1 | 8,594.0 | 6,123.3 | 7,898.1 | 7,874.0 | -279.6 | 9,756.2 |
| EBIT growth | -6.4% | 0.6% | 40.3% | -22.5% | 0.3% | -2916.2% | -102.9% | -3.4% |
| EBIT margin | 34.2% | 36.3% | 35.5% | 27.1% | 35.9% | 34.3% | | 45.5% |
| Non-recurring items [+] | 545.6 | 1,032.5 | 5,177.1 | 142.3 | 322.2 | 107.6 | 194.6 | |
| Legal settlement | | | 4,850.0 | | | | | |
| Other income (expense), net | 3,275.8 | 2,318.1 | 75.2 | 240.4 | -212.0 | 236.4 | 474.2 | -104.5 |
| Pre-tax income | 10,822.6 | 9,931.7 | 3,492.1 | 6,221.4 | 7,363.9 | 8,002.8 | 0.0 | 9,651.7 |
| Income taxes | 2,747.5 | 1,999.4 | 95.3 | 1,787.6 | 2,732.6 | 2,172.7 | 0.0 | 2,856.9 |
| Tax rate | 25.4% | 20.1% | 2.7% | 28.7% | 37.1% | 27.1% | | 29.6% |
| Minority interest | 122.8 | 123.9 | 121.4 | | | | | |
| Earnings from continuing ops | 7,952.3 | 7,808.4 | 3,275.4 | 4,433.8 | 4,631.3 | 5,830.1 | | 6,794.8 |
| Earnings from discontinued ops | | | | | | | | 354.7 |
| Net income | 7,952.3 | 7,808.4 | 3,275.4 | 4,433.8 | 4,631.3 | 5,830.1 | 0.0 | 7,149.5 |
| Net margin | 33.6% | 32.7% | 13.5% | 19.6% | 21.0% | 25.4% | | 33.3% |
| |
| Basic EPS [+] | | $3.66 | $1.51 | $2.04 | $2.11 | $2.63 | | $3.01 |
| Growth | | 142.4% | -26.0% | -3.3% | -19.8% | | | -2.2% |
| Diluted EPS [+] | | $3.64 | $1.49 | $2.03 | $2.10 | $2.62 | | $2.98 |
| Growth | | 144.3% | -26.6% | -3.3% | -19.8% | | | -1.9% |
| |
| Dividends per share | $1.52 | $1.52 | $1.52 | | | | | |
| Growth | 0.0% | 0.0% | | | | | | |
| |
| Shares outstanding (basic) [+] | | 2,133.4 | 2,169.1 | 2,173.4 | 2,194.9 | 2,216.8 | | 2,255.4 |
| Growth | | -1.6% | -0.2% | -1.0% | -1.0% | | | -1.5% |
| Shares outstanding (diluted) [+] | | 2,145.2 | 2,198.3 | 2,184.1 | 2,205.4 | 2,225.2 | | 2,276.9 |
| Growth | | -2.4% | 0.6% | -1.0% | -0.9% | | | -1.8% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|